Janssen Pharmaceuticals, Inc.

Janssen Pharmaceuticals, Inc., a for-profit pharmaceutical manufacturer headquartered in Titusville, New Jersey, supplies branded pharmaceutical products to the Department of Defense and Veterans Affairs as a prime contractor under full-and-open competition, with no set-aside designations across its federal footprint. The company operates 100% as a prime, competing across multiple indefinite delivery vehicles and a Federal Supply Schedule contract rather than through subcontractor relationships.

Janssen's federal capability portfolio centers on the manufacture and distribution of branded pharmaceutical preparations—including Risperdal (risperidone tablets), itraconazole capsules, haloperidol lactate injections, and unit-dose tablets and capsules—to military treatment facilities and VA medical facilities worldwide. All work is performed at the company's Titusville facility. Representative recent awards include a $20.5 million delivery order from DLA Troop Support Medical in December 2024 for unspecified medical products, a $7.7 thousand delivery order in December 2025 for other medical supplies, and multiple orders for Risperdal 1 mg unit-dose tablets ranging from $733 to $1.5 thousand awarded in summer 2025. The company also holds a $4.405 billion Federal Supply Schedule contract under the Pharmaceuticals and Drugs (FSS-61-IB) schedule issued by the Veterans Integrated Service Network 12, effective through September 2029, through which VA agencies place routine orders.

Customer concentration is extreme and tilted heavily toward the VA. The top customer by potential value—Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12—anchors $4.405 billion (98.8% of combined potential value) of the company's federal footprint, while Defense Logistics Agency Troop Support Medical places high-volume, low-dollar delivery orders totaling $58.4 million across 169 awards. The ranking by award count diverges sharply from dollars: DLA Troop Support Medical dominates volume (169 awards, 50.6% of all awards) but contributes less than 2% of total potential value, whereas the single VA FSS contract represents 98.8% of dollars.

Janssen places work under multiple DLA indefinite delivery contracts and basic ordering agreements: an Indefinite Delivery Contract (SPM2D012D0001) with 149 task orders totaling $1.5 million, an IDC (DLA12091D0582) with 34 task orders, an IDC (DLA12089D0296) with 29 task orders, and BOAs (DLA12086D0674 and DLA12085D0562) with 24 and 23 task orders respectively. Award activity has been sparse in recent years—two awards in 2021 and 2022, one in 2023, two in 2024, and three in 2025—with only $8 thousand in combined potential value reaching completion inside the next twenty-four months, indicating minimal near-term recompete exposure. The company's federal portfolio carries a combined potential value of $4.46 billion but only $30.1 million has been obligated, reflecting the FSS contract's large ceiling relative to actual task-order spend to date.